Jacqueline A. Nicholas, MD, MPH - Setting the Stage for Bruton’s Tyrosine Kinase Inhibitors in Relapsing Multiple Sclerosis: Where Does the Evidence Stand?

Please visit answersincme.com/BAV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses Bruton’s tyrosine kinase (BTK) inhibitors in relapsing multiple sclerosis (MS). Upon completion of this activity, participants should be better able to: Recognize the biologic rationale for therapeutically targeting BTK in MS; Describe the clinical impact of late-stage emerging BTK inhibitors in relapsing MS; and Outline clinical considerations for the future use of BTK inhibitors in the management of relapsing MS.

There are no comments yet.

Please log in to write the first comment.